[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"monoclonal-antibody\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:monoclonal-antibody":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100556968","phase-3-a-phase--clinical-study-of-hlx22-in-combination-with-trastuzumab-and-chemotherapy-for-the-treatment-of-gastroesophageal-junction-and-gastric-cancer-100556968",false,"NCT06532006","A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer","Inclusion Criteria:\n\n1. Male\u002Ffemale who are at least 18 years of age on the day of signing the informed consent.\n2. With histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.\n3. Had measurable disease as assessed by IRRC according to the RECIST v1.1, the target lesion must not be a bone metastatic lesion only.\n4. HER2-positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH+ or FISH, as assessed by a central laboratory on a primary or metastatic tumor.\n5. ECOG PS within 7 days before randomization: 0-1.\n6. Expected survival ≥ 6 months.\n7. Had adequate organ function\n\nExclusion Criteria:\n\n1. Patients with other malignant tumors within 2 years before the randomization.\n2. Evidence of disease progression within 6 months (before randomization) after completion of prior neoadjuvant or adjuvant chemotherapy (or both) or radiotherapy for gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.\n3. Previous treatment with any HER2-target therapy.\n4. Active gastrointestinal bleeding\n5. Presence of central nervous system (CNS) metastases.\n6. Left ventricular ejection fraction (LVEF) \\\u003C 55%.\n7. Subjects who had known history of severe allergy to any monoclonal antibody or any component of study treatment.","ALL","18 Years",{"count":19,"type":20},550,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced\u002Fmetastatic adenocarcinoma of the gastric and\u002For gastroesophageal junction (G\u002FGEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).",[26,27,28,29],"Gastroesophageal-junction Cancer","Monoclonal Antibody","Gastric Cancer","HER2-positive Gastric Cancer","RECRUITING","2026-02-24",{"date":33,"type":34},"2026-02-27","ACTUAL",{"date":36,"type":34},"2024-11-22",{"date":38,"type":20},"2028-09-01",{"name":40,"class":41},"Shanghai Henlius Biotech","INDUSTRY",208]